S K Kundu

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.

S K Kundu, David Katzenstein, Lincoln E. Moses et al. · Proceedings of the National Academy of Sciences · 1992 · 55 citations · Full text

Safety and Efficacy of Polyethylene Glycol-Modified Interleukin-2 and Zidovudine in Human Immunodeficiency Virus Type 1 Infection: A Phase I/II Study

Robin Wood, José G. Montoya, S K Kundu et al. · The Journal of Infectious Diseases · 1993 · 48 citations

A Randomized, Placebo-Controlled Study of the Immunogenicity of Human Immunodeficiency Virus (HIV) rgp160 Vaccine in HIV-Infected Subjects with >=400/mm3 CD4 T Lymphocytes (AIDS Clinical Trials Group Protocol 137)

Fred Valentine, S K Kundu, Patrick Haslett et al. · The Journal of Infectious Diseases · 1996 · 47 citations

Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein

Marc Dupuis, S K Kundu, T. C. Merigan · The Journal of Immunology · 1995 · 38 citations

Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection.

S K Kundu, T. C. Merigan · PubMed · 1991 · 22 citations · Full text

Immunology, Pathology, Cd4 T Cell Responses +21